secwatch.observer — SEC 8-K summary
======================================

Issuer:     MiNK Therapeutics, Inc. (INKT)
CIK:        0001840229
Form:       8-K
Filed at:   2022-08-05T23:59:59+00:00
Accession:  0001193125-22-213655
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

MiNK Therapeutics enters amended intercompany services agreement with Agenus effective April 1, 2022
--------------------------------------------------------------------------------

- New agreement covers G&A, R&D, and shared services; MiNK pays 10% of Agenus' G&A costs.
- R&D services charged at pass-through costs plus allocation of employee costs.
- Shared services no charge if proportional; facility/insurance use with proportionate payment.
- Either party may terminate with 60 days' notice; individual services 30 days.
- Agreement retroactive to April 1, 2022, amends September 2021 agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840229/000119312522213655/0001193125-22-213655-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840229/000119312522213655/d357005d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-213655

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer